Scarica l'app Stockscreener
0.347
2.03%
-0.0072
Dopo l'orario di chiusura:
.36
0.013
+3.75%
Cognition Therapeutics Inc Borsa (CGTX) Ultime notizie
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Rating of “Buy” by Analysts - Defense World
Cognition Therapeutics reports promising Alzheimer’s study results By Investing.com - Investing.com South Africa
Cognition Therapeutics reports promising Alzheimer’s study results - Investing.com
Cognition Therapeutics Presents Results at AD/PD 2025 - GlobeNewswire
Breakthrough: Cognition's Alzheimer's Drug Reduces Multiple Disease Markers in Phase 2 Trial - Stock Titan
Equities Analysts Set Expectations for CGTX FY2025 Earnings - Defense World
Contrasting Alpha Cognition (NASDAQ:ACOG) & Cognition Therapeutics (NASDAQ:CGTX) - Defense World
HC Wainwright Has Bearish Estimate for CGTX Q1 Earnings - Defense World
Dementia Associated With Alzheimer’s Disease Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
What is HC Wainwright’s Forecast for CGTX Q1 Earnings? - Defense World
Cognition Therapeutics to Report Biomarker Results from - GlobeNewswire
Cognition Therapeutics to present Alzheimer’s study results By Investing.com - Investing.com South Africa
Agitation in Alzheimer's Disease Market: Analysis - openPR.com
Cognition to Reveal Biomarker Findings Next Week - Baystreet.ca
Cognition Therapeutics to present Alzheimer’s study results - Investing.com India
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer's Disease in Podium Presentation at AD/PD 2025 - The Manila Times
Cognition Therapeutics to Present Phase 2 SHINE Study Biomarker Results for Zervimesine at AD/PD 2025 Conference - Nasdaq
Game-Changing Alzheimer's Treatment: New Phase 2 Data Reveals Multiple Positive Biomarkers - Stock Titan
Cognition Therapeutics (NASDAQ:CGTX) Price Target Cut to $5.00 by Analysts at HC Wainwright - Defense World
Cognition Therapeutics stock price target cut to $5 at H.C. Wainwright - Investing.com Canada
Cognition Therapeutics Earnings Call: Progress Amid Challenges - MSN
Chardan Capital Has Lowered Expectations for Cognition Therapeutics (NASDAQ:CGTX) Stock Price - Defense World
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2024 Earnings Call Transcript - MSN
Brookline Capital lifts Cognition Therapeutics stock to $7 target By Investing.com - Investing.com Canada
Cognition Therapeutics Inc (CGTX) Q4 2024 Earnings Call Highlights: Strategic Focus on ... By GuruFocus - Investing.com Canada
New Horizons in Lewy Body Dementia Market Exploring Future - openPR.com
Cognition Therapeutics Advances Alzheimer’s and DLB Trials - TipRanks
Earnings call transcript: Cognition Therapeutics Q4 2024 sees $34M net loss - Investing.com Australia
Cognition Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
COGNITION THERAPEUTICS Earnings Results: $CGTX Reports Quarterly Earnings - Nasdaq
COGNITION THERAPEUTICS INC SEC 10-K Report - TradingView
Cognition Therapeutics, Inc. Reports Positive Phase 2 Results for Zervimesine in Dementia with Lewy Bodies and Alzheimer's Disease, Plans Advancement to Late-Stage Trials - Nasdaq
Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update - GlobeNewswire
Lewy Body Dementia Market to Show Remarkable Growth Trends from - openPR
Alzheimer's disease Clinical and Non-Clinical Studies, Key - openPR
Cognition Therapeutics (CGTX) Projected to Post Quarterly Earnings on Thursday - Defense World
Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results - The Manila Times
Cognition Therapeutics Q4 Earnings: Key Date Revealed for Crucial Neurodegenerative Treatment Updates - StockTitan
Cognition Therapeutics at Life Sciences Forum: Progress in Alzheimer’s and Lewy Body Dementia - Investing.com UK
Cognition Therapeutics shifts to Nasdaq Capital Market By Investing.com - Investing.com Australia
Cognition Therapeutics shifts to Nasdaq Capital Market - Investing.com India
Cognition Therapeutics, Inc. Transitions to Nasdaq Capital Market Following Compliance Notification - Nasdaq
Cognition Therapeutics Granted Extension to Meet Nasdaq - GlobeNewswire
Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange - EIN News
Cognition Therapeutics Gets 180-Day Lifeline to Maintain Nasdaq Listing Status - Stock Titan
Oral Drug Therapy for Slowing Progression of Alzheimer’s and Lewy Body Dementia with Lisa Ricciardi and Dr. Tony Caggiano Cognition Therapeutics TRANSCRIPT - Audacy
Cognition Therapeutics, Inc. CEO Lisa Ricciardi to Present at Life Sciences Virtual Investor Conference on Alzheimer’s Disease Advances - Nasdaq
Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference - GlobeNewswire
Cognition Therapeutics CEO to Share Alzheimer's Drug Progress at Investor Conference - StockTitan
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Head to Head Analysis: Cognition Therapeutics (NASDAQ:CGTX) versus Creative Medical Technology (NASDAQ:CELZ) - Defense World
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):